T Cells in COVID-19 - Translating research findings into clinical options

Analysis of SARS-CoV-2–specific T cells is important to understand their role during acute disease and in long-term protection after infection or vaccination. Though studying these rare cells comes with challenges, gained insights offer great opportunities in fighting COVID-19. This webinar will cover both sides.

 

There is growing evidence that SARS-CoV-2–specific T cells play an important role in the recovery from COVID-19. Researchers have reported the presence of a SARS-CoV-2–specific memory T cell population in the blood of convalescent donors. These cells could be used for treating COVID-19 patients in certain cases.

 

At Miltenyi Biotec, we offer a complete workflow for the study of virus-specific T cells. Also, several preparation methods for clinical-grade cell products using our CliniMACS® Technology have been described.^1-3 In 2021, Antonio Perez et al. reported improvement of symptoms in nine patients in a phase 1 clinical trial using convalescent donor-derived CD45RA-depleted memory T cells. The study indicates the potential of adoptive cell therapy to treat COVID-19.⁴ More research is needed to further develop this new exciting field of cell therapy.

 

1 Cooper et al. (2021) Front. Immunol. 11: 598402. 2 Leung et al. (2020) Adv. Cell Gene Ther. 2020: e101. 3 Ferreras et al. (2021) Front. Cell Dev. Biol. 9: 620730. 4 Pérez-Martínez et al. (2021) EClinicalMedicine 39: 101086.

 

Learning Objectives